Back to top
more

Nektar Therapeutics (NKTR)

(Delayed Data from NSDQ)

$1.70 USD

1.70
1,443,556

-0.05 (-2.86%)

Updated May 21, 2024 04:00 PM ET

After-Market: $1.70 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 248)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

CannTrust (CTST) to Report Q2 Earnings: What's in Store?

On CannTrust's (CTST) second-quarter earnings call, investor focus will be on the company's efforts to resolve matters regarding the non-compliant report issued by Health Canada.

Nektar (NKTR) Down 7% Since Last Earnings Report: Can It Rebound?

Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Neena Mishra headshot

Cancer-Fighting Stocks & ETF: What You Need to Know

Many biotech stocks soared after they presented very promising cancer treatment results at the ASCO conference

Nektar (NKTR) in Focus: Stock Moves 8.8% Higher

Nektar (NKTR) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Neena Mishra headshot

Why Cancer-Fighting Stocks & ETFs Are Soaring

The cancer immunotherapy ETF is soaring today as some of its holdings presented very promising results at the ASCO conference. Find out more on the podcast.

Nektar (NKTR) Announces Formation of CNS-Focused Subsidiary

Nektar (NKTR) forms wholly-owned subsidiary, Inheris Biopharm, focusing on CNS pipeline. The subsidiary will mainly be responsible for potential commercialization of under review pain drug, NKTR-181.

3 Small Drug Stocks Poised to Beat Q1 Earnings Estimates

So far this earnings season, the going seems to be good for the medical sector. Let us take a glance at a few small drug companies, which are likely to beat on Q1 earnings.

Nektar (NKTR) Q1 Earnings & Revenues Beat, Decline Y/Y

Nektar's (NKTR) earnings and sales beat estimates in the first quarter. The company is progressing well with its pipeline candidates.

Nektar Therapeutics (NKTR) Reports Q1 Loss, Tops Revenue Estimates

Nektar (NKTR) delivered earnings and revenue surprises of 4.23% and 10.90%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

What's in the Cards for Nektar (NKTR) This Earnings Season?

The focus will be on Nektar Therapeutics' (NKTR) pipeline progress when the company reports first-quarter results.

Earnings Preview: Nektar Therapeutics (NKTR) Q1 Earnings Expected to Decline

Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Nektar (NKTR) Down 17.1% Since Last Earnings Report: Can It Rebound?

Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Stock Market News For Mar 7, 2019

Benchmarks ended in the red on Wednesday after a slew of weak economic reports weighed on the markets.

Nektar (NKTR) Q4 Earnings Beat, NKTR-181 Review Extended

Nektar's (NKTR) earnings and sales beat estimates in the fourth quarter. The FDA extends the review period for NKTR-181 NDA by three months.

What's in the Cards for Nektar (NKTR) This Earnings Season?

Nektar Therapeutics (NKTR) will report fourth-quarter results on Feb 28. Investors are expected to focus on pipeline progress.

Nektar, ImaginAb Enter Into Immuno-Oncology Collaboration

Nektar (NKTR) and ImaginAb enter into a license and clinical trial collaboration, allowing Nektar to use ImaginAb's immuno-oncology imaging technology.

BioXcel Surges on Fast Track Designation to Agitation Drug

BioXcel (BTAI) soars after the FDA granted Fast Track designation to its lead candidate, BXCL501.

Nektar (NKTR) Up 7.7% Since Last Earnings Report: Can It Continue?

Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Nektar (NKTR) Catches Eye: Stock Jumps 8.7%

Nektar (NKTR) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Nektar (NKTR) Q3 Earnings & Sales Beat Estimates, Shares Up

Nektar's (NKTR) earnings and sales beat estimates in the third quarter. The company enters oncology clinical collaboration with Pfizer to evaluate NKTR-214 combination therapy.

Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates

Nektar (NKTR) delivered earnings and revenue surprises of 12.50% and 11.87%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

What's in the Cards for Nektar (NKTR) This Earnings Season?

Nektar Therapeutics (NKTR) will report third-quarter results on Nov 7. Investors are expected to focus on pipeline progress.

Analysts Estimate Nektar Therapeutics (NKTR) to Report a Decline in Earnings: What to Look Out for

Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Implied Volatility Surging for Nektar Therapeutics (NKTR) Stock Options

Investors need to pay close attention to Nektar Therapeutics (NKTR) stock based on the movements in the options market lately.